Lonza Group AG Asset Resilience Ratio
Lonza Group AG asset resilience ratio. Lonza Group AG (LONN) has an Asset Resilience Ratio of 3.04% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LONN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lonza Group AG (2004–2025)
Asset resilience ratio of Lonza Group AG from 2004 to 2025. This chart shows how Lonza Group AG's Asset Resilience Ratio has changed over time. See Lonza Group AG free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Lonza Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lonza Group AG balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF600.00 Million | 3.04% |
| Total Liquid Assets | CHF600.00 Million | 3.04% |
Asset Resilience Insights
- Limited Liquidity: Lonza Group AG maintains only 3.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lonza Group AG Industry Peers by Asset Resilience Ratio
Compare Lonza Group AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sotera Health Co
NASDAQ:SHC |
Diagnostics & Research | 0.01% |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB |
Diagnostics & Research | 13.43% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Lonza Group AG Asset Resilience Ratio by Year (2004–2025)
Lonza Group AG asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Lonza Group AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.54% | CHF481.00 Million ≈ $608.11 Million |
CHF18.97 Billion ≈ $23.98 Billion |
-3.98pp |
| 2024-12-31 | 6.51% | CHF1.28 Billion ≈ $1.62 Billion |
CHF19.73 Billion ≈ $24.95 Billion |
-1.82pp |
| 2023-12-31 | 8.33% | CHF1.40 Billion ≈ $1.77 Billion |
CHF16.85 Billion ≈ $21.30 Billion |
-3.15pp |
| 2022-12-31 | 11.48% | CHF1.99 Billion ≈ $2.52 Billion |
CHF17.36 Billion ≈ $21.94 Billion |
-2.07pp |
| 2021-12-31 | 13.55% | CHF2.23 Billion ≈ $2.82 Billion |
CHF16.46 Billion ≈ $20.81 Billion |
+13.84pp |
| 2020-12-31 | -0.29% | CHF-43.00 Million ≈ $-54.36 Million |
CHF14.62 Billion ≈ $18.49 Billion |
-0.03pp |
| 2019-12-31 | -0.27% | CHF-37.00 Million ≈ $-46.78 Million |
CHF13.84 Billion ≈ $17.50 Billion |
-0.71pp |
| 2018-12-31 | 0.44% | CHF61.00 Million ≈ $77.12 Million |
CHF13.92 Billion ≈ $17.60 Billion |
+0.23pp |
| 2017-12-31 | 0.21% | CHF29.00 Million ≈ $36.66 Million |
CHF13.83 Billion ≈ $17.49 Billion |
-0.73pp |
| 2016-12-31 | 0.94% | CHF64.00 Million ≈ $80.91 Million |
CHF6.83 Billion ≈ $8.63 Billion |
+0.89pp |
| 2015-12-31 | 0.05% | CHF3.00 Million ≈ $3.79 Million |
CHF6.25 Billion ≈ $7.90 Billion |
-0.09pp |
| 2014-12-31 | 0.14% | CHF9.00 Million ≈ $11.38 Million |
CHF6.44 Billion ≈ $8.14 Billion |
-0.27pp |
| 2013-12-31 | 0.41% | CHF26.00 Million ≈ $32.87 Million |
CHF6.37 Billion ≈ $8.06 Billion |
+1.58pp |
| 2012-12-31 | -1.17% | CHF-83.00 Million ≈ $-104.93 Million |
CHF7.10 Billion ≈ $8.98 Billion |
-0.37pp |
| 2011-12-31 | -0.80% | CHF-56.00 Million ≈ $-70.80 Million |
CHF7.02 Billion ≈ $8.88 Billion |
-0.82pp |
| 2009-12-31 | 0.02% | CHF1.00 Million ≈ $1.26 Million |
CHF4.94 Billion ≈ $6.25 Billion |
-0.06pp |
| 2008-12-31 | 0.08% | CHF4.00 Million ≈ $5.06 Million |
CHF4.93 Billion ≈ $6.24 Billion |
+0.65pp |
| 2007-12-31 | -0.57% | CHF-28.00 Million ≈ $-35.40 Million |
CHF4.95 Billion ≈ $6.26 Billion |
-0.26pp |
| 2006-12-31 | -0.31% | CHF-12.00 Million ≈ $-15.17 Million |
CHF3.91 Billion ≈ $4.95 Billion |
-0.03pp |
| 2005-12-31 | -0.28% | CHF-12.00 Million ≈ $-15.17 Million |
CHF4.33 Billion ≈ $5.48 Billion |
+0.05pp |
| 2004-12-31 | -0.33% | CHF-11.00 Million ≈ $-13.91 Million |
CHF3.34 Billion ≈ $4.22 Billion |
-- |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biol… Read more